Schultes Birgit C
EVP, Chief Scientific Officer
Schultes Birgit C has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Mar 3, 2026.
On the most recent filing, Schultes Birgit C is listed as EVP, Chief Scientific Officer at Intellia Therapeutics, Inc. Inside the rolling window, Schultes Birgit C reported no open-market purchases and 1 open-market sale totaling $78K in NTLA.
Companies traded
Other insiders at NTLA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$78K
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Oct 1, 2025 | NTLA | Sale | $539 |
Frequently asked questions
How many SEC Form 4 filings has Schultes Birgit C made?
Schultes Birgit C has filed 3 SEC Form 4 filings (3 transaction rows) across 1 company since 2025.
Which companies does Schultes Birgit C trade?
Schultes Birgit C has filed SEC Form 4 disclosures for 1 company, including NTLA.
When was Schultes Birgit C's most recent SEC Form 4 filing?
Schultes Birgit C's most recent SEC Form 4 filing on Tracefour is dated Mar 3, 2026.
What is Schultes Birgit C's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Schultes Birgit C is listed as EVP, Chief Scientific Officer.
What is Schultes Birgit C's total buy and sell value in the current window?
Inside the rolling retention window, Schultes Birgit C bought $0 and sold $78K based on SEC Form 4 filings.
What was Schultes Birgit C's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 8,508 NTLA shares on 2026-01-05, worth $78K, per SEC Form 4 filings.